Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial by Ritchlin, C. et al.
s 
 
 
 
Ritchlin, C. et al. (2014) Efficacy and safety of the anti-IL-12/23 p40 
monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis 
despite conventional non-biological and biological anti-tumour necrosis 
factor therapy: 6-month and 1-year results of the phase 3, multicentre, 
double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of 
the Rheumatic Diseases, 73(6), pp. 990-999. 
 
 
Copyright © 2014 BMJ Publishing Group 
This work is made available under the Creative Commons Attribution Non 
Commercial  3.0 License (CC BY-NC 3.0)     
 
 
 
 
Version: Published 
 
 
 
http://eprints.gla.ac.uk/104757 
 
 
 
Deposited on:  08 April 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
EXTENDED REPORT
Efﬁcacy and safety of the anti-IL-12/23 p40
monoclonal antibody, ustekinumab, in patients
with active psoriatic arthritis despite conventional
non-biological and biological anti-tumour necrosis
factor therapy: 6-month and 1-year results of the
phase 3, multicentre, double-blind, placebo-
controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin,1 Proton Rahman,2 Arthur Kavanaugh,3 Iain B McInnes,4
Lluis Puig,5 Shu Li,6 Yuhua Wang,6 Yaung-Kaung Shen,6 Mittie K Doyle,7
Alan M Mendelsohn,6 Alice B Gottlieb,8 on behalf of the PSUMMIT 2 Study Group
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2013-204655).
For numbered afﬁliations see
end of article
Correspondence to
Dr Christopher Ritchlin, Allergy,
Immunology & Rheumatology
Division, University of
Rochester Medical Center, 601
Elmwood Avenue, Box 695,
Rochester, NY 14642, USA;
Christopher_Ritchlin@URMC.
Rochester.edu
Received 23 September 2013
Revised 3 January 2014
Accepted 5 January 2014
Published Online First
30 January 2014
▸ http://dx.doi.org/10.1136/
annrheumdis-2013-204741
▸ http://dx.doi.org/10.1136/
annrheumdis-2013-204934
To cite: Ritchlin C,
Rahman P, Kavanaugh A,
et al. Ann Rheum Dis
2014;73:990–999.
ABSTRACT
Objective Assess ustekinumab efﬁcacy (week 24/week
52) and safety (week 16/week 24/week 60) in patients
with active psoriatic arthritis (PsA) despite treatment
with conventional and/or biological anti-tumour necrosis
factor (TNF) agents.
Methods In this phase 3, multicentre, placebo-
controlled trial, 312 adults with active PsA were
randomised (stratiﬁed by site, weight (≤100 kg/
>100 kg), methotrexate use) to ustekinumab 45 mg or
90 mg at week 0, week 4, q12 weeks or placebo at
week 0, week 4, week 16 and crossover to ustekinumab
45 mg at week 24, week 28 and week 40. At week 16,
patients with <5% improvement in tender/swollen joint
counts entered blinded early escape (placebo→45 mg,
45 mg→90 mg, 90 mg→90 mg). The primary endpoint
was ≥20% improvement in American College of
Rheumatology (ACR20) criteria at week 24. Secondary
endpoints included week 24 Health Assessment
Questionnaire-Disability Index (HAQ-DI) improvement,
ACR50, ACR70 and ≥75% improvement in Psoriasis
Area and Severity Index (PASI75). Efﬁcacy was assessed
in all patients, anti-TNF-naïve (n=132) patients and anti-
TNF-experienced (n=180) patients.
Results More ustekinumab-treated (43.8% combined)
than placebo-treated (20.2%) patients achieved ACR20
at week 24 (p<0.001). Signiﬁcant treatment differences
were observed for week 24 HAQ-DI improvement
(p<0.001), ACR50 (p≤0.05) and PASI75 (p<0.001); all
beneﬁts were sustained through week 52. Among
patients previously treated with ≥1 TNF inhibitor,
sustained ustekinumab efﬁcacy was also observed (week
24 combined vs placebo: ACR20 35.6% vs 14.5%,
PASI75 47.1% vs 2.0%, median HAQ-DI change
−0.13 vs 0.0; week 52 ustekinumab-treated: ACR20
38.9%, PASI75 43.4%, median HAQ-DI change −0.13).
No unexpected adverse events were observed through
week 60.
Conclusions The interleukin-12/23 inhibitor
ustekinumab (45/90 mg q12 weeks) yielded signiﬁcant
and sustained improvements in PsA signs/symptoms in a
diverse population of patients with active PsA, including
anti-TNF-experienced PsA patients.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, seronegative,
inﬂammatory joint disease that commonly involves
not only peripheral joints, but also the spine,
entheses (attachment sites where tendons, ligaments
and joint capsules attach to bone) and soft tissues
(tendonitis and dactylitis).1 2 PsA leads to functional
impairment, reduced quality of life and increased
comorbidity/mortality,3–8 often requiring treatment
with tumour necrosis factor-α(TNF) antagonists.9
Ustekinumab (Stelara; Janssen Biotech, Inc.;
Horsham, Pennsylvania, USA), a human immuno-
globulin G1κ mAb that binds to the common p40
subunit shared by IL-12 and IL-23, was approved for
treatment of moderate-to-severe psoriasis based upon
large phase 3 trials.10–12 The efﬁcacy of ustekinumab
in active PsA was also evaluated in a phase 2 trial13
and in the large phase 3 PSUMMIT 1 trial,14 which
included only patients naïve to biological anti-TNF
treatments. In these anti-TNF-naïve patients, usteki-
numab signiﬁcantly improved active PsA signs/symp-
toms and demonstrated an acceptable safety proﬁle
through 1 year.14 Results of the PSUMMIT 2 trial,
including patients with and without prior exposure
to anti-TNF agents, through week 60 are presented.
METHODS
Patients
Adult patients with active PsA for ≥6 months, despite
≥3 months of disease-modifying antirheumatic drug
(DMARD) therapy, ≥4 weeks of non-steroidal anti-
inﬂammatory drugs (NSAIDs) therapy and/or ≥8
(etanercept, adalimumab, golimumab, certolizumab-
pegol) or 14 (inﬂiximab) continuous weeks of
TNF-antagonist therapy (or less if patient was intoler-
ant of anti-TNF therapies) were eligible. The protocol
speciﬁed 150–180 of 300 randomised patients must
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have been previously treated with biological anti-TNF agents.
Active PsA was deﬁned as ≥5/66 swollen and ≥5/68 tender joints
at screening/baseline, screening C-reactive protein (CRP) ≥6.0 mg/
L (modiﬁed to ≥3.0 mg/L after study start; upper limit of normal
10 mg/L) and active/documented history of plaque psoriasis. A
history of active tuberculosis (TB) was prohibited, but patients
with newly documented latent TB or anti-TNF-experienced
patients with a history of treated latent TB within 3 years were eli-
gible with initiation of appropriate treatment. Concomitant
methotrexate (MTX) was permitted if started ≥3 months prior to
study start and at a stable dose (≤25 mg/week) for ≥4 weeks.
Concomitant NSAIDs and oral corticosteroids (≤10 mg prednis-
one/day) were permitted if stable for ≥2 weeks. Allowed concomi-
tant medications were to remain stable through week 52. Patients
could not have previously received any anti-IL-12/23 agent or aba-
tacept. Receipt of alefacept within 3 months and/or B cell and
Tcell-depleting agents (including rituximab), efalizumab or natali-
zumab within 12 months of screening excluded patient participa-
tion. DMARDs other than MTX were not allowed within 4 weeks
prior to or during trial participation (see online supplement).
Study design
In the phase 3, multicentre, randomised, placebo-controlled
PSUMMIT 2 study (NCT01077362, EudraCT 2009-012265-
60), patients who met the ClASsiﬁcation Criteria for Psoriatic
ARthritis (CASPAR)15 were randomly assigned to receive
ustekinumab 45 mg, 90 mg or placebo at week 0, week 4 and
every 12 weeks (q12 weeks) thereafter. Randomisation was
accomplished using dynamic central randomisation, employ-
ing an algorithm implemented in an interactive voice/web
response system, and was stratiﬁed by study site, baseline
body weight (≤100 kg, >100 kg) and baseline MTX usage
(yes/no). The randomisation method was minimisation with a
biased-coin assignment (1:1:1). At week 16, patients with
<5% improvement in tender and swollen joints entered
blinded early escape (EE); patients receiving placebo switched
to ustekinumab 45 mg, those receiving ustekinumab 45 mg
increased to 90 mg and patients receiving ustekinumab 90 mg
continued with blinded 90 mg dosing. Placebo patients who
did not EE crossed over to receive ustekinumab 45 mg at
week 24, week 28 and week 40 (see online supplement).
Assessments
Clinical efﬁcacy was primarily assessed using the American
College of Rheumatology (ACR) response criteria16; response
per the 28-joint disease activity score employing C-reactive
protein (DAS28-CRP), that is, European League Against
Rheumatism (EULAR) response of good or moderate and
Table 1 Baseline patient demographics and disease characteristics among all randomised patients
Placebo UST 45 mg UST 90 mg
All patients (N) 104 103 105
Women 53 (51.0) 55 (53.4) 56 (53.3)
Age (years) 48.0 (38.5 to 56.0) 49.0 (40.0 to 56.0) 48.0 (41.0 to 57.0)
Body mass index (kg/m2) 30.5 (26.8 to 35.7) 30.2 (25.5 to 36.9) 30.3 (25.3 to 37.1)
Duration of disease (years)
Psoriatic arthritis 5.5 (2.3 to 12.2) 5.3 (2.3 to 12.2) 4.5 (1.7 to 10.3)
Psoriasis 11.4 (6.0 to 22.0) 13.3 (5.0 to 24.4) 11.3 (4.5 to 21.4)
Swollen joint count (0–66) 11.0 (7.0 to 18.0) 12.0 (8.0 to 19.0) 11.0 (7.0 to 17.0)
Tender joint count (0–68) 21.0 (11.0 to 30.0) 22.0 (15.0 to 33.0) 22.0 (14.0 to 36.0)
CRP (mg/L) 8.5 (4.6 to 22.0) 13.0 (4.5 to 36.3) 10.1 (4.8 to 19.8)
HAQ-DI score (0–3) 1.3 (0.8 to 1.8) 1.4 (0.8 to 1.9) 1.3 (0.8 to 1.9)
DAS28-CRP score 5.2 (4.4 to 5.9) 5.6 (4.9 to 6.3) 5.3 (4.7 to 6.0)
Patients with dactylitis in ≥1 digit 38 (36.5) 48 (46.6) 41 (39.0)
Dactylitis score (1–60) 7.0 (3.0 to 14.0) 5.0 (2.0 to 13.0) 7.0 (2.0 to 15.0)
Patients with enthesitis 73 (70.2) 72 (69.9) 76 (72.4)
Enthesitis score (1–15) 4.0 (2.0 to 8.0) 6.0 (3.0 to 9.0) 5.0 (3.0 to 8.0)
Patients with spondylitis/peripheral joint involvement 22 (21.2) 26 (25.2) 22 (21.0)
BASDAI score (1–10) 6.6 (5.8 to 7.8) 7.6 (5.7 to 8.2) 7.1 (5.8 to 7.9)
Patients with ≥3% BSA involved with psoriasis 80 (76.9) 80 (77.7) 81 (77.1)
PASI score (0–72) 7.9 (4.5 to 16.0) 8.6 (4.5 to 18.3) 8.8 (4.5 to 18.0)
DLQI score (0–30) 11.0 (5.0 to 16.5) 11.0 (6.0 to 18.0) 10.0 (6.0 to 18.0)
FACIT-Fatigue score (0–52) 28.0 (17.0 to 34.5) 26.0 (17.0 to 33.0) 24.5 (17.0 to 34.5)
SF-36 summary scores (n) 104 102 104
Mental component (0–100) 41.8 (31.6 to 53.5) 43.7 (33.0 to 54.6) 41.4 (33.8 to 54.9)
Physical component (0–100) 29.4 (23.3 to 36.2) 28.0 (22.6 to 34.0) 28.2 (21.8 to 33.6)
Current medication use
Methotrexate 49 (47.1) 54 (52.4) 52 (49.5)
Dose (mg/week), mean/median 17.4/17.5 17.2/15.0 15.9/15.0
Oral corticosteroids 13 (12.5) 21 (20.4) 16 (15.2)
Dose (mg/day), mean/median 8.0/7.5 7.0/5.0 7.5/7.5
NSAIDs 77 (74.0) 72 (69.9) 70 (66.7)
Data are reported as n (%) or median (IQR) unless noted otherwise.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BSA, body surface area; CRP, C-reactive protein; DAS28-CRP, 28-joint disease activity score employing CRP; DLQI,
Dermatology Life Quality Index; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; NSAIDs,
non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; pts, patients; SF-36, 36-item short-form healthy survey; UST, ustekinumab.
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DAS28-CRP score <2.617–20; and the Psoriasis Area and
Severity Index (PASI) score (0–72)21 among patients with ≥3%
of body surface area (BSA) affected by psoriasis at baseline.
Physical function was measured using the Health Assessment
Questionnaire-Disability Index (HAQ-DI),22 a ≥0.3 unit
improvement (decrease), which is considered clinically import-
ant in PsA.23
Additional assessments included (1) dactylitis—assessed in
20 digits of the hands and feet on a scale of 0 to 3 (0=no dac-
tylitis; 3=severe dactylitis); (2) entheseal tenderness/pain—
scored in 15 body sites (0=absent; 1=present) using the
PsA-modiﬁed (to include left and right insertion of the plantar
fascia) Maastricht Ankylosing Spondylitis Enthesitis Score
(MASES)24; and (3) Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI)—a self-assessment tool for ankylosing
spondylitis25 administered to patients with baseline spondylitis
and peripheral joint involvement; note that the BASDAI has
not been validated in PsA. A BASDAI decrease of 50% or two
points is considered clinically meaningful in ankylosing
spondylitis.26
Patient quality of life was assessed using the 36-item short-
form (SF-36) health survey27 and, among patients with ≥3%
BSA affected by psoriasis at baseline, the Dermatology Life
Quality Index (DLQI).28 Fatigue during the previous week was
measured using the 13-item Functional Assessment of Chronic
Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire.29 Safety
evaluations included adverse events (AEs) and routine labora-
tory analyses; immunogenicity determinations are detailed
online.
Statistical analysis
The primary endpoint was the proportion of patients with
≥20% improvement in ACR (ACR20) response at week 24.
Major clinical secondary endpoints, all at week 24, included
change in HAQ-DI, and proportions of patients achieving
≥75% improvement in PASI (PASI75), ≥50% improvement in
ACR (ACR50) and ≥70% improvement in ACR (ACR70) cri-
teria. To control for multiplicity for the primary and major sec-
ondary endpoint analyses, the latter were performed
sequentially, contingent upon the success of the primary end-
point analysis. Primary and major secondary analyses were
intent-to-treat.
Patients who used prohibited medication or discontinued
study agent because of lack of efﬁcacy were considered non-
responders for binary endpoints and had baseline values carried
forward for continuous endpoints through week 52. For
patients who qualiﬁed for EE at week 16, week 16 data were
carried forward through week 24. After week 24, available data
were used for EE patients. Patients with missing week 24 data
were considered non-responders for ACR and PASI responses
and had the last observation carried forward for the week 24
change in HAQ-DI. Otherwise, missing data were not imputed.
Treatment differences at week 24 were assessed using Cochran–
Mantel–Haenszel tests for binary variables and analyses of vari-
ance on the van der Waerden normal scores30 for continuous
variables. Both tests adjusted for baseline MTX use (also see
online supplement).
RESULTS
Disposition and baseline characteristics
Patient disposition and baseline demographic and disease
characteristics are shown in online supplementary ﬁgure S1 and
table 1, respectively. Among the anti-TNF-experienced patients,
>70% had an inadequate response to or were intolerant of
prior anti-TNF treatment and >50% had received ≥2 anti-TNF
agents (see online supplementary table S1).
Joints, dactylitis and enthesitis
Signiﬁcantly higher proportions of ustekinumab-treated
(43.8%–combined, 43.7%–45 mg, 43.8%–90 mg) than placebo-
treated (20.2%) patients achieved week 24 ACR20 response (all
p<0.001). Signiﬁcant differences were observed for the more
stringent ACR50 response at week 24 (20.2%–combined,
17.5%–45 mg, 22.9%–90 mg vs 6.7% placebo; all p<0.05);
numerical but not signiﬁcant differences were observed for
ACR70 response. Response rates were sustained through week
52 (see online supplementary table S3, ﬁgure 1A; recall that EE
rules were not applied after week 24). At week 24, ACR20
response was achieved regardless of concomitant MTX therapy
or body weight, although the treatment difference appeared
numerically larger in patients not receiving MTX versus those
receiving MTX and in patients weighing >100 kg vs ≤100 kg,
in both cases due to a higher placebo response rate in patients
receiving MTX or weighing ≤100 kg (table 2, ﬁgure 1B,C).
At week 24, signiﬁcantly higher proportions of ustekinumab-
treated than placebo-treated patients achieved a DAS28-CRP/
EULAR response (all p<0.001; see online supplementary
table S2); responses were sustained through week 52 (see online
supplementary table S3), with continued improvement over time
(see online supplementary ﬁgures S2A,B). Ustekinumab treatment
also yielded a signiﬁcantly higher proportion of patients with
DAS28-CRP score <2.6 at week 24. By week 52, 19.6% of
ustekinumab-treated patients had a DAS28-CRP score <2.6.
Among the 221 randomised patients with baseline enthesitis,
signiﬁcantly lower proportions of ustekinumab-treated than
placebo-treated patients had residual enthesitis at week 24 (all
p<0.05; see online supplementary table S2). Patients treated
with ustekinumab 90 mg exhibited signiﬁcantly greater improve-
ment in enthesitis (MASES) at week 24 versus placebo
(p<0.01). Numeric, but not signiﬁcant, improvement was
observed among the smaller number (n=127) of patients with
baseline dactylitis in the 90 mg group versus placebo. By week
52, median percent improvements in dactylitis and enthesitis
scores among ustekinumab-treated patients were 95.0% and
50.0%, respectively (see online supplementary table S3 and
ﬁgures S3A,B). Among patients with baseline concomitant spon-
dylitis, numerically greater BASDAI response rates among
ustekinumab-treated than placebo-treated patients at week 24
were generally observed (see online supplementary table S2).
Skin disease
In patients with ≥3% BSA baseline psoriasis skin involvement,
signiﬁcantly (all p<0.001) greater proportions of ustekinumab-
treated than placebo-treated patients achieved PASI75 response or
≥90% improvement in PASI score (PASI90) at week 24 (table 2,
ﬁgure 2A, see online supplementary table S2). By week 52,
60.6% and 43.7% of ustekinumab-treated patients achieved
PASI75 and PASI90 responses, respectively (ﬁgure 2A; online sup-
plementary table S3). At week 24, PASI75 response was achieved
regardless of concomitant MTX therapy or body weight,
although the treatment difference appeared numerically larger in
patients not receiving MTX versus those receiving MTX and in
patients weighing >100 vs ≤100 kg, both resulting from higher
placebo response rates in patients receiving MTX or weighing
≤100 kg (table 2, ﬁgure 2B,C).
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Physical function and quality of life
Improvements in HAQ-DI scores at week 24 were signiﬁcantly
greater among ustekinumab-treated than placebo-treated
patients (p≤0.001; table 2). See supplementary tables S2 and S3
for further details of physical function and quality-of-life
measures.
Efﬁcacy by prior anti-TNF exposure
A majority of the 180 anti-TNF-experienced patients had
received ≥2 such agents and >70% had discontinued prior
agent(s) due to lack of efﬁcacy/intolerance (table S1). At week
24, ustekinumab efﬁcacy was also observed in the 180
anti-TNF-experienced patients, among whom week 24 ACR20
and PASI75 response rates were 35.6% and 47.1%, respectively,
for combined ustekinumab-treated vs 14.5% and 2.0%, respect-
ively, for placebo-treated patients (both p<0.01; table 2,
ﬁgures 1D,E and 2D,E; online supplementary ﬁgure S4). Also
among anti-TNF-experienced patients, median changes in
HAQ-DI scores at week 24 were –0.13 for combined
ustekinumab-treated vs 0.0 for placebo-treated patients
(p<0.05). Response to ustekinumab through 1 year appeared
more pronounced in patients with only 1 vs ≥2 prior anti-TNF
agents, although assessments are limited by small sample sizes
(table 3). Based on posthoc regression analyses performed, no
consistent predictors were identiﬁed for ACR20 and ACR50
responses (data not shown).
Figure 1 Proportions of patients achieving ACR20 response over time through week 52 for all patients (A), patients with MTX use (B), patients
without MTX use (C), anti-TNF-naïve patients (D) and anti-TNF-experienced patients (E), with the vertical dotted lines indicating the time after which
data-handling rules changed as noted in the footnote to the ﬁgure. ACR20, at least 20% improvement in the American College of Rheumatology
response criteria; MTX, methotrexate; TNF, tumour necrosis factor-α; UST, ustekinumab.
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Immunogenicity
See online supplement.
Safety
Safety ﬁndings are provided through week 16 (placebo-
controlled period) and week 24 in table 4 and through week 60
in online supplementary table S4.
Among ustekinumab-treated and placebo-treated patients,
61.8% and 54.8% reported AEs, 27.1% and 24.0% had
investigator-reported infections, 1.9% and 7.7% discontinued
study agent because of an AE, and 0.5% and 4.8% had serious
AEs, respectively, through week 16. Increases in the occurrence of
AEs through week 60 were consistent with the additional usteki-
numab exposure accrued from week 16 forward without obvious
dose trend. Serious AEs (table 4; online supplementary table S4)
occurred in 5.2% (15/287) of all ustekinumab-treated patients
through week 60 (rate=11.82/100 patient-years). Serious AE rates
in ustekinumab-treated patients receiving and not receiving MTX
were 3.4% and 7.1%, respectively.
No patients died, and no cases of TB were reported through
week 60. Through week 16, one placebo-treated and no
ustekinumab-treated patients reported serious infections.
Through week 60, two ustekinumab-treated patients reported
serious infections (rate=0.74/100 patient-years). One patient
(90 mg) had septic shock/severe dehydration, with Candida spp.
in her stool; systemic candidiasis was not identiﬁed. Another
patient (90 mg) had a serious infection through week 60 (bacter-
aemia in a 50-year-old man (per AMA guidelines) (methicillin-
sensitive Staphylococcus aureus) believed to result from psoriatic
plaque infection and subsequent knee arthritis). Both patients
recovered without sequelae following appropriate therapy. Two
patients had malignancies reported through week 60
(placebo→45 mg breast cancer, 90 mg squamous cell carcinoma
in situ in an area of cleared plaque psoriasis); both were
anti-TNF-experienced patients.
No major cardiovascular AEs (MACE) were observed through
week 16. Through week 60, three patients (2–45 mg, 1–90 mg,
all anti-TNF-experienced patients) had myocardial infarctions
Table 2 Summary of primary and major secondary efficacy endpoints at week 24 among randomised patients
Placebo
(N=104)
UST 45 mg
(N=103)
UST 90 mg
(N=105)
Combined UST
(N=208)
ACR20 response (1° endpoint)
Difference (CI)
21 (20.2) 45 (43.7)***
23.5 (11.2 to 35.8)
46 (43.8)***
23.6 (11.4 to 35.8)
91 (43.8)***
ACR20 by MTX use
Yes 14/49 (28.6) 27/54 (50.0) 21/52 (40.4) 48/106 (45.3)
No 7/55 (12.7) 18/49 (36.7) 25/53 (47.2) 43/102 (42.2)
ACR20 by body weight
≤100 kg 17/74 (23.0) 32/74 (43.2) 34/73 (46.6) 66/147 (44.9)
>100 kg 4/30 (13.3) 13/29 (44.8) 12/31 (38.7) 25/60 (41.7)
ACR20 by anti-TNF use
Anti-TNF-naïve 12/42 (28.6) 23/43 (53.5) 26/47 (55.3) 49/90 (54.4)
Anti-TNF-experienced 9/62 (14.5) 22/60 (36.7) 20/58 (34.5) 42/118 (35.6)
ACR50 response (major 2° endpoint) 7 (6.7) 18 (17.5)* 24 (22.9)** 42 (20.2)**
Difference (CI) 10.7 (2.0 to 19.5) 16.1 (6.8 to 25.5)
ACR70 response (major 2° endpoint) 3 (2.9) 7 (6.8) 9 (8.6) 16 (7.7)
Difference (CI) 3.9 (−1.9 to 9.7) 5.7 (−0.6 to 11.9)
PASI75 response† (major 2° endpoint) 4/80 (5.0) 41/80 (51.3)*** 45/81 (55.6)*** 86/161 (53.4)***
Difference (CI) 46.3 (34.3 to 58.2) 50.6 (38.7 to 62.4)
PASI75 by MTX use
Yes 3/29 (10.3) 19/39 (48.7) 22/39 (56.4) 41/78 (52.6)
No 1/51 (2.0) 22/41 (53.7) 23/42 (54.8) 45/83 (54.2)
PASI75 by body weight
≤100 kg 4/54 (7.4) 31/58 (53.4) 32/57 (56.1) 63/115 (54.8)
>100 kg 0/26 (0.0) 10/22 (45.5) 13/24 (54.2) 23/46 (50.0)
PASI75 by anti-TNF use
Anti-TNF-naïve 3/30 (10.0) 21/36 (58.3) 25/40 (62.5) 46/76 (60.5)
Anti-TNF-experienced 1/50 (2.0) 20/44 (45.5) 20/41 (48.8) 40/85 (47.1)
HAQ-DI score
Change from baseline (major 2° endpoint) 0.00 (−0.13 to 0.13) −0.13 (−0.38 to 0.00)** −0.25 (−0.50 to 0.00)*** −0.25 (−0.38 to 0.00)***
Difference (CI) 0.13 (0.00 to 0.30) 0.25 (0.10 to 0.30)
HAQ-DI change from baseline
Anti-TNF-naïve, N 42 43 47 90
0.00 (−0.25 to 0.25) −0.25 (−0.50 to 0.00) −0.25 (−0.50 to 0.00) −0.25 (−0.50 to 0.00)
Anti-TNF-experienced, N 62 60 58 118
0.00 (−0.13 to 0.13) −0.13 (−0.38 to 0.00) −0.19 (−0.38 to 0.00) −0.13 (−0.38 to 0.00)
Data are reported as n (%), n/N (%) or median (IQR).
*, ** and *** indicate p<0.05, 0.01 and 0.001, respectively, versus placebo.
†Among patient with ≥3% BSA psoriasis involvement at baseline.
ACR, American College of Rheumatology; BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; PASI, Psoriasis Area and Severity
Index; TNF, tumour necrosis factor-α; UST, ustekinumab.
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reported; only two events were adjudicated as a myocardial
infarction (rate=0.74/100 patient-years). These patients had car-
diovascular risk factors independent of PsA identiﬁed (history of
stroke, hypertension, smoking and/or symptoms of metabolic
syndrome).
DISCUSSION
In this multicentre, phase 3, double-blind, placebo-controlled
trial, subcutaneous ustekinumab was effective and demonstrated
an acceptable safety proﬁle among patients with active PsA,
more than half of whom had previously received ≥1 anti-TNF
agent. The study’s primary endpoint was met, with signiﬁcantly
higher week 24 ACR20 response rates among ustekinumab-
treated than placebo-treated patients. Although efﬁcacy was
observed as early as week 4, maximal efﬁcacy was not reached
until week 24 through week 28. Ustekinumab also demonstrated
superiority to placebo when clinical response was assessed using
the DAS28-CRP score and when improvements in skin disease
and physical function were evaluated. There was also numerical
superiority in BASDAI measurements in patients with spondyl-
itis, indicating that ustekinumab may improve spinal disease,
although this effect was not studied systematically and the
BASDAI has not been validated for use in patients with PsA.
Thus, PSUMMIT 2 efﬁcacy ﬁndings are consistent with those
Figure 2 Proportions of patients achieving PASI75 response over time through week 52 for all patients (A), patients with MTX use (B), patients
without MTX use (C), anti-TNF-naïve patients (D) and anti-TNF-experienced patients (E), with data handling rule changes as noted in the footnote to
the ﬁgure. MTX, methotrexate; PASI75, at least 75% improvement in the Psoriasis Area and Severity Index response criteria; TNF, tumour necrosis
factor-α; UST, ustekinumab.
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observed in the larger phase 3, multicentre, placebo-controlled
PSUMMIT 1 trial of 615 biologically-naïve patients with active
PsA through week 52, in which ustekinumab was shown to sig-
niﬁcantly improve signs and symptoms of disease and patient
physical function.14 Note that the results of combined radio-
graphic ﬁndings across the PSUMMIT 1 and PSUMMIT 2 trials
are the subject of a forthcoming publication.31
Clinical improvements translated into signiﬁcantly improved
physical function and quality of life among ustekinumab-treated
patients. Nearly half of the ustekinumab-treated patients
achieved a clinically meaningful improvement from baseline to
week 24 in FACIT-Fatigue score compared with approximately
one-quarter of placebo-treated patients.
Although the PSUMMIT 2 trial was not designed to compare
the efﬁcacy or safety of concomitant MTX versus no concomi-
tant MTX treatment, or of anti-TNF-experienced versus
anti-TNF-naïve patient groups, ustekinumab treatment appeared
effective regardless of concomitant MTX use and, importantly,
also among all combined anti-TNF-experienced patients,
although to a lesser degree than was observed in anti-TNF-naïve
patients. Lower clinical response rates in anti-TNF-experienced
patients who switch to a second biological agent are well docu-
mented for rheumatoid arthritis,32 psoriasis12 33 and now in the
PSUMMIT 2 PsA trial (table 3). In a longitudinal observational
study of 95 PsA patients who switched from one to another
TNF inhibitor, signiﬁcantly poorer responses were noted com-
pared with patients who did not switch (n=344) (ACR50
response: 22.5% vs 40.0%, DAS28 remission: 28.2% vs
54.1%).34 Similarly, among 548 Danish PsA patients who
switched from their ﬁrst TNF inhibitor to a second biological
agent, response rates were lower with the second treatment
(p<0.01 for each agent vs initial TNF inhibitor).35 Thus,
response to ustekinumab may possibly be reduced in
anti-TNF-experienced patients, particularly those previously
treated with multiple anti-TNF agents, given ﬁndings observed
through 1 year of ustekinumab therapy in PSUMMIT 2 (table 3)
and those observed with other biological agents as noted above.
While the reason(s) for the lower response rates remain unclear,
it is possible that prior treatment with TNF inhibitors alters the
natural history and clinical response to other agents in patients
with psoriasis and/or PsA, or that such patients may be recalci-
trant to multiple therapies. This is an important area of future
research.
Patient discontinuation rates were 29.4% and 15.9% among
anti-TNF-experienced and anti-TNF-naïve patients, respectively;
this difference was particularly notable in placebo patients (that
is, 42% vs 12% of patients) and could have been related to the
longer duration and greater activity of disease that speciﬁcally
characterised anti-TNF-experienced patients. These cofactors
may also have contributed to the lower response rates in
anti-TNF-experienced patients.
We observed an apparent diminution of response at week 16
(prior to the third dose of study agent), but also noted a peak
effect at weeks 24–28. These observations could be related to
the 12-week dosing interval and potential achievement of
steady-state pharmacokinetics at weeks 24–28 and/or a low
serum drug level in some patients at week 16. In psoriasis,
partial loss of response to ustekinumab has been observed in
some patients during the 2-week period preceding the next uste-
kinumab injection in observational studies and in clinical
trials.10 11 33 Thus, as with many drugs, shorter or longer
dosing intervals may prove optimal for some patients. Results of
Table 3 Summary of efficacy at week 24 and week 52 among randomised patients by number of prior biological anti-TNF exposure (1 vs >1)
Placebo→UST 45 mg UST 45 mg UST 90 mg Combined UST
Week 24 (N) 62 60 58 118
ACR20 response by number of prior biological anti-TNF agents
1 prior agent 3/30 (10.0) 8/23 (34.8) 10/28 (35.7) 18/51 (35.3)
>1 prior agent 6/32 (18.8) 14/37 (37.8) 10/30 (33.3) 24/67 (35.8)
PASI75 response by number of prior biological anti-TNF agents*
1 prior agent 0/27 (0.0) 7/15 (46.7) 12/21 (57.1) 19/36 (52.8)
>1 prior agent 1/23 (4.3) 13/29 (44.8) 8/20 (40.0) 21/49 (42.9)
HAQ-DI change from baseline by number of prior biological anti-TNF agents
1 prior agent (n) 30
0.00 (0.00 to 0.25)
23
−0.13 (−0.38 to 0.00)
28
−0.25 (−0.50 to 0.00)
51
−0.25 (−0.50 to 0.00)
>1 prior agent (n) 32
0.00 (−0.13 to 0.00)
37
−0.13 (−0.38 to 0.00)
30
0.00 (−0.38 to 0.00)
67
−0.13 (−0.38 to 0.00)
Week 52 (N) 43† 60 58 118
ACR20 response by number of prior biological anti-TNF agents
1 prior agent 12/22 (54.5) 11/21 (52.4) 14/28 (50.0) 25/49 (51.0)
>1 prior agent 4/18 (22.2) 9/33 (27.3) 8/26 (30.8) 17/59 (28.8)
PASI75 response by number of prior biological anti-TNF agents*
1 prior agent 8/20 (40.0) 5/13 (38.5) 12/21 (57.1) 17/34 (50.0)
>1 prior agent 5/10 (50.0) 8/23 (34.8) 8/19 (42.1) 16/42 (38.1)
HAQ-DI change from baseline by number of prior biological anti-TNF agents
1 prior agent (n) 22
0.00 (−0.13 to 0.13)
21
−0.25 (−0.50 to 0.00)
28
−0.19 (−0.50 to 0.00)
49
−0.25 (−0.50 to 0.00)
>1 prior agent (n) 18
0.00 (−0.13 to 0.13)
33
−0.13 (−0.38 to 0.00)
26
0.00 (−0.50 to 0.00)
59
0.00 (−0.50 to 0.00)
Data are reported as n (%), n/N (%) or median (IQR).
*Among patient with ≥3% BSA psoriasis skin involvement at baseline.
†Excludes patients who did not receive ustekinumab.
ACR, American College of Rheumatology; BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI, Psoriasis Area and Severity Index; TNF, tumour
necrosis factor-α; UST, ustekinumab.
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a retrospective case review of 129 ustekinumab-treated patients
with psoriasis have demonstrated a reduction in efﬁcacy for
individuals weighing 90–100 kg and also receiving 45 mg.36
Consistently, patients in PSUMMIT 1 and PSUMMIT 2 trials
weighing >100 kg demonstrated an overall lower response than
those weighing ≤100 kg. Pharmacokinetic factors and differ-
ences in the dynamics of cytokine down-regulation, coupled
with varied responses of cell targets in joint, entheseal or skin
lesions, may contribute to the delayed onset of ustekinumab
peak response observed in PsA. This response contrasts with
that observed with anti-TNF agents, which typically demonstrate
higher proportions of patients with signiﬁcant ACR20 efﬁcacy
at earlier time points,37 although week 28 and week 52 ACR20,
ACR50 and ACR70 response rates in the anti-TNF-naïve
patients in PSUMMIT 2, as well as in PSUMMIT 1 trial,14
appear consistent with those of other biological agents.
Importantly, no such comparisons can be made for
anti-TNF-experienced patients because no other trials have been
conducted in a population this severe.
The safety of ustekinumab therapy in the treatment of patients
with psoriasis and PsA has been compared during the placebo-
controlled periods,38 and through 339 and 5 years40 of therapy;
safety ﬁndings through week 60 in this study of patients with PsA
appear to be consistent. Speciﬁcally, AEs and serious AEs were
similar between ustekinumab-treated and placebo-treated
patients through week 16. Through week 60, no deaths or cases
of TB were reported, and one case of septic shock with Candida
spp. identiﬁed in the stool was reported. Other serious infections
were rare (one patient had bacteraemia), and two malignancies
(squamous cell carcinoma in situ, breast cancer, both in
anti-TNF-experienced patients) were reported through week 60.
The two adjudicated events of myocardial infarction after week
16 occurred in anti-TNF-experienced patients with established
cardiovascular risk factors.
Thus, the PSUMMIT 2 trial data through week 60 indicate
that ustekinumab, representing an alternate mechanism of
action to approved biological PsA therapies, induced signiﬁcant
improvement in the joint, enthesitis/dactylitis and skin symp-
toms of active PsA in a population including ∼58%
anti-TNF-experienced patients, with an acceptable safety proﬁle.
These data also provide further support for the role of the
IL-12/23 p40 cytokines in PsA pathogenesis.
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Table 4 Summary of safety through week 16 and week 24 among all patients who received at least one study agent injection
Week 16 (placebo-controlled period)* Week 24*
Placebo
(N=104)
UST
45 mg
(N=103)
UST
90 mg
(N=104)
Combined
UST
(N=207)
Placebo
(N=104)
Placebo→UST
45 mg (N=31)
UST
45 mg
(N=103)
UST
90 mg
(N=104)
All UST
(N=238)
Average weeks of follow-up 15.1 16.0 15.9 16.0 19.4 8.2 23.8 23.3 21.6
AEs, n (%) 57 (54.8) 65 (63.1) 63 (60.6) 128 (61.8) 66 (63.5) 13 (41.9) 73 (70.9) 72 (69.2) 158 (66.4)
Common AEs†
Nasopharyngitis 5 (4.8) 8 (7.8) 10 (9.6) 18 (8.7) 8 (7.7) 0 (0.0) 10 (9.7) 13 (12.5) 23 (9.7)
Headache 4 (3.8) 5 (4.9) 5 (4.8) 10 (4.8) 5 (4.8) 2 (6.5) 7 (6.8) 6 (5.8) 15 (6.3)
Arthralgia 1 (1.0) 5 (4.9) 4 (3.8) 9 (4.3) –‡ – – – –
Upper respiratory tract
infection
4 (3.8) 5 (4.9) 3 (2.9) 8 (3.9) 4 (3.8) 3 (9.7) 10 (9.7) 6 (5.8) 19 (8.0)
Fatigue 0 (0.0) 5 (4.9) 2 (1.9) 7 (3.4) – – – – –
Nausea 2 (1.9) 4 (3.9) 3 (2.9) 7 (3.4) – – – – –
Back pain 0 (0.0) 1 (1.0) 4 (3.8) 5 (2.4) – – – – –
Diarrhoea 3 (2.9) 4 (3.9) 1 (1.0) 5 (2.4) – – – – –
Oropharyngeal pain 0 (0.0) 4 (3.9) 1 (1.0) 5 (2.4) – – – – –
Psoriasis 3 (2.9) 4 (3.9) 1 (1.0) 5 (2.4) – – – – –
Psoriatic arthropathy 5 (4.8) 4 (3.9) 1 (1.0) 5 (2.4) – – – – –
Discontinued study agent
due to AEs, n (%)
8 (7.7) 2 (1.9) 2 (1.9) 4 (1.9) 11 (10.6) 0 (0.0) 2 (1.9) 3 (2.9) 5 (2.1)
Serious AEs, n (%)§ 5 (4.8) 0 (0.0) 1 (1.0) 1 (0.5) 5 (4.8) 1 (3.2) 0 (0.0) 2 (1.9) 3 (1.3)
Investigator-reported infection,
n (%)
25 (24.0) 30 (29.1) 26 (25.0) 56 (27.1) 30 (29.7) 4 (12.9) 42 (40.8) 36 (34.6) 82 (34.5)
AEs with ‘–’ did not meet the criteria for a ‘common’ events at that time point (see footnotes † and ‡).
*At week 16, patients with <5% improvement from baseline in both tender and swollen joint counts entered blinded early escape, such that patients receiving ustekinumab 45 mg
increased to 90 mg and patients receiving placebo switched to ustekinumab 45 mg; patients receiving ustekinumab 90 mg continued with their blinded dose regimen. AEs through
week 24 are cumulative and include those reported through week 16.
†AEs occurring in >2% of patients in the combined ustekinumab (week 16) or > 5% of patients in the all ustekinumab (week 24) groups; AEs are ordered according to decreasing
frequency for the combined ustekinumab group at week 16.
‡AEs did not occur in >5% of patients in the All UST group.
§Serious AEs through week 16 included hyperglycaemia, depression, pyrexia, chronic cholecystitis/hypertension/cerebrovascular insufficiency, and interstitial lung disease in five
placebo-treated patients and acute renal injury/syncope in one ustekinumab 90 mg patient. From weeks 16 to 24, an additional placebo patient had a serious event of suicidal ideation
after early escape to ustekinumab 45 mg and an additional ustekinumab 90 mg patient had a serious event of arthritis.
AE, adverse event; UST, ustekinumab.
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